$IOVA $350M ATM 😬

Obesity drug bubble on a diet: stocks slim down as hype calories burn off From Endpoints News

$ONC Announces IMDELLTRA Royalty Purchase Agreement for up to $950M with $RPRX businesswire.com/news/home/2025…

$VALN Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ in the U.S. ca.finance.yahoo.com/news/valneva-a…

$AXGN FDA has extended the PDUFA goal date for the BLA for Avance Nerve Graft by three months to 12/05/25

$STSS Announces over $400M Private Placement seeking to Establish the Largest Solana Digital Asset Treasury Strategy

$XERS Announces Orange Book Listing of U.S. Patent for Recorlev Recorlev now holds four Orange Book-listed patents to 2040

$VALN

$SCPH halt

$MNKD to acquire $SCPH Upfront cash payment of $5.35/share plus CVR

$BBIO to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

$SRPT HCW reiterates Sell rating. PT $5

$GLMD Announces Digital Asset Management Strategy Including Potential Allocation Of Up To 50% Of Cash Reserves To Be Used For Digital Asset Purchases

$PDSB Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months

$ALLR Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

$GMAB Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan in Advanced Endometrial Cancer (EC)

$IXHL Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder. The results confirm statistically significant and clinically meaningful improvements across every key endpoint assessed in the study globenewswire.com/news-release/2…